D-1081-2019 Class II Terminated

Recalled by RemedyRepack Inc. — Indiana, PA

FDA drug recall D-1081-2019 was initiated by RemedyRepack Inc. on Mar 14, 2019 and is designated Class II. Reason for recall: CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA). The recall status is terminated (terminated Apr 11, 2019). Affected quantity: 33 blister cards of 30 = 990 tablets.

Recall details

Product Type
Drugs
Report Date
Apr 17, 2019
Initiation Date
Mar 14, 2019
Termination Date
Apr 11, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
33 blister cards of 30 = 990 tablets

Product description

Losartan 50mg Tablet, 30 count each blister card.

Reason for recall

CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).

Distribution pattern

Product was distributed to one sole customer, Miami, FL.

Code information

70518-0588-01, Lot #: J0328416-101518, Exp. Date: 10/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1081-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1081-2019. Report a data issue: hello@regdatalab.com.